Exec Chat: New CEO Of Digital Therapeutics Alliance Says Reimbursement Remains Big Issue
In an interview with Medtech Insight, Andy Molnar, new CEO of the Digital Therapeutics Alliance, outlines some of the big issues facing the digital therapeutics industry, which has seen tremendous growth during the pandemic.
You may also be interested in...
Big Health will use its $75m in new funding to scale the business, with plans to launch six new digital therapeutics by 2024. Former US FDA official Anand Shah will join its board of directors.
Medtech Insight spoke to Pear Therapeutics CEO Corey McMann about the emerging digital therapeutics market and his company’s future now that it has the first PDT covered by Medicaid.
Experts foresee the digital therapeutics market growing to $6bn-$9bn by 2025, driven in part by tech-empowered consumers and patients looking for solutions to better manage their own health and conditions. For medtechs, collaborations with software-driven start-ups will be key to harnessing personalized data and differentiating themselves in the marketplace.